Skip to Content

How effective is Verzenio?

Medically reviewed by Carmen Fookes, BPharm. Last updated on July 1, 2020.

Official Answer

by Drugs.com
  • Women taking Verzenio plus aromatase inhibitors experienced a longer progression-free survival than those taking placebo (28.2 months compared to 14.8 months).
  • 55% of women experienced a complete or partial response to Verzenio plus an aromatase inhibitor.
  • Women taking Verzenio plus fulvestrant were less likely to experience an “event” that impacted on their disease progression (49.8% vs 70.4%).
  • For women taking Verzenio as monotherapy, 19.7% saw their tumors shrink by 30% or more.

Verzenio (abemaciclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. It may be used for the treatment of advanced hormone receptor-positive, HER2-negative metastatic breast cancer. It may be given when cancer has progressed or spread to other parts of the body after treatments such as anti-estrogens or chemotherapy have already been given.

Verzenio belongs to the class of medicines known as CDK 4/6 inhibitors which help to reduce the growth and spread of cancer cells in the body.

Clinical trials have shown that for women taking Verzenio plus anastrozole or letrozole:

  • Progression-free survival (the length of time without a worsening of their breast cancer) was longer with Verzenio: 28.2 months for women taking the Verzenio combination compared with 14.8 months for women taking the placebo combination
  • 55.4% of women taking the Verzenio combination had either a complete response or a partial response compared to only 40.2% taking placebo.

For women taking Verzenio in combination with fulvestrant:

  • Fewer women experienced an “event” that impacted on their progression-free survival: 49.8% of women taking Verzenio experienced an event compared to 70.4% of those taking the placebo combination
  • Overall survival was 46.7 months in women taking the Verzenio combination compared with 37.3 months in those taking the placebo combination
  • 48.1% of women responded to the Verzenio combination compared with 21% of women taking the placebo combination.

For women taking Verzenio as monotherapy:

  • 19.7% of women saw their tumors shrink by 30% or more
  • The average duration of response was 8.6 months.

Verzenio is usually taken twice daily. When taken regularly, consistent blood levels are achieved within five days. Gastrointestinal side effects, such as diarrhea, typically occur in the first month of treatment and can affect up to 81% of patients. The average time to onset of diarrhea was 6 to 8 days. Diarrhea can be severe and requires monitoring and proper management.

References

Related Medical Questions

Drug Information

Related Support Groups